Medications to Manage Sulfur Burps on Ozempic (semaglutide 0.5-2 mg): First-Line and Beyond

What the Ozempic label records

The Ozempic label's common adverse reactions, at 5% or more, are nausea, vomiting, diarrhea, abdominal pain and constipation [1]. Belching appears in a separate list of reactions below 5%, under the label's term eructation: 0% of placebo-treated adults, 2.7% on 0.5 mg and 1.1% on 1 mg, in placebo-controlled trials in adults with type 2 diabetes (mean exposure to Ozempic 32.9 weeks) [1]. The label also gives flatulence at 0.8%, 0.4% and 1.5%, and gastroesophageal reflux disease at 0%, 1.9% and 1.5% (placebo, 0.5 mg, 1 mg) [1].

The label for semaglutide tablets (Rybelsus and Ozempic tablets) reports eructation in 2% on 14 mg, 0.6% on 7 mg and 0% on placebo [2].

The label counts belching. It does not record odor, so a sulfur smell is not a separate entry.

What the guidelines say, for a different diagnosis

The nearest published guidance is for gastroparesis, which is a different diagnosis. The American College of Gastroenterology guideline says medical treatment of gastroparesis means prokinetic and antiemetic drugs, and that the approved options, including metoclopramide, do not adequately address clinical need [3]. It describes domperidone, erythromycin (mainly short term) and centrally acting antidepressants as unapproved or off-label, with most of these treatments resting on open-label trials and small numbers [3]. The guideline addresses diagnosed gastroparesis. It does not establish any of these drugs as a treatment for belching during semaglutide treatment.

Taking other oral medicines with Ozempic

The label says Ozempic delays gastric emptying and may affect absorption of oral medicines taken at the same time, and that caution should be exercised. It adds that in clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medicines to any clinically relevant degree [1]. With semaglutide tablets, levothyroxine total exposure rose 33% [2].

When burping is not the main problem

The label's serious GI warnings describe something heavier than burping. Severe gastrointestinal adverse reactions were reported more often with Ozempic (0.4% on 0.5 mg, 0.8% on 1 mg) than with placebo (0%) [1]. Postmarketing reports include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. The label says Ozempic is not recommended in patients with severe gastroparesis, and it does not state that semaglutide causes gastroparesis [1]. Acute pancreatitis is also listed; the label describes its signs as persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1].